Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
06/2005
06/01/2005EP1534721A1 Process for controlling the hydrate mix of a compound
06/01/2005EP1534720A1 Mitochondrially targeted antioxidants
06/01/2005EP1534717A1 Beta-lactamase inhibitor prodrug
06/01/2005EP1534715A1 Furopyridine and furopyrimidine derivatives for the treatment of hyper-proliferative disorders
06/01/2005EP1534707A1 Substituted 2,4-dihydro-pyrrolo (3, 4-b) -quinolin-9-one derivatives useful as phosphodiesterase inhibitors
06/01/2005EP1534706A1 Furanthiazole derivatives as heparanase inhibitors
06/01/2005EP1534704A1 Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
06/01/2005EP1534703A2 Antagonists of melanin concentrating hormone receptor
06/01/2005EP1534700A1 Novel thiophene derivatives, preparation method thereof and pharmaceutical compositions containing same
06/01/2005EP1534696A1 Therapeutic compounds for treating dyslipidemic conditions
06/01/2005EP1534695A2 Tyrosine kinase inhibitors
06/01/2005EP1534693A2 1, 3-diamino-2-hydroxypropane prodrug derivatives
06/01/2005EP1534690A1 2-substituted bicyclic benzoheterocyclic compounds and their use as sodium channel blockers
06/01/2005EP1534687A1 Pyrimidine compounds
06/01/2005EP1534686A2 Nf-kb inhibitors and uses thereof
06/01/2005EP1534683A2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use
06/01/2005EP1534682A1 Novel molecules derived from noraporphine
06/01/2005EP1534681A1 Substituted quinoline ccr5 receptor antagonists
06/01/2005EP1534680A1 Prenylation inhibitors and methods of their synthesis and use
06/01/2005EP1534679A2 Inhibitors of post-amadori advanced glycation end products
06/01/2005EP1534678A1 Pleuromutilin derivatives as antimicrobbials
06/01/2005EP1534677A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1
06/01/2005EP1534676A1 Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
06/01/2005EP1534675A1 Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo[3.1.0]hexane derivatives as muscarinic receptor antagonists
06/01/2005EP1534674A2 Cytotoxic agents containing novel potent taxanes and their therapeutic use
06/01/2005EP1534673A1 An improved process for the preparation of xanthophyll crystals
06/01/2005EP1534672A1 Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
06/01/2005EP1534668A1 Crystalline solid form of (2s-5z)-2-amino-7-(ethanimidoylamino)-2-methylhept-5-enoic acid
06/01/2005EP1534667A1 Muscarinic agonists
06/01/2005EP1534666A1 Compounds for modulating the glycolosis enzyme complex and/or transaminase complex
06/01/2005EP1534663A1 N-bridged selective androgen receptor modulators and methods of use thereof
06/01/2005EP1534658A2 Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
06/01/2005EP1534512A1 Coated particles, methods of making and using
06/01/2005EP1534508A1 Embossable and writable multilaminate backing construction
06/01/2005EP1534391A1 Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders
06/01/2005EP1534390A2 3'- (2z)- 1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4h-pyrazol-4-ylidene]hydrazino]-2'-hydroxy- 1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
06/01/2005EP1534389A2 Pyrazolopyrimidines as kinase inhibitors
06/01/2005EP1534368A1 Medicament dispenser
06/01/2005EP1534367A1 Medicament dispenser
06/01/2005EP1534346A2 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues
06/01/2005EP1534340A2 Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto
06/01/2005EP1534339A1 Topical anhydrous and ethanol-free ascomycin compositions
06/01/2005EP1534338A1 Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
06/01/2005EP1534324A2 Tumor specific oligosaccharide epitopes and use thereof
06/01/2005EP1534322A1 Minibrain homologous proteins involved in the regulation of energy homeostasis
06/01/2005EP1534314A1 A nutritional and therapeutic composition of an insulin sensitizer and a peptide fraction
06/01/2005EP1534313A2 Ophthalmologic irrigation solutions and method
06/01/2005EP1534311A2 Method for identifying modulators of ion channels
06/01/2005EP1534309A2 Parathyroid hormone antagonists and uses thereof
06/01/2005EP1534308A2 Peptides with growth inhibitory action
06/01/2005EP1534303A1 Antimicrobial charged polymers that exhibit resistance to lysomal degradation during kidney filtration and renal passage, compositions and method of use thereof
06/01/2005EP1534302A2 Arginine silicate inositol complex and use thereof
06/01/2005EP1534300A2 3, 10, and 12a substituted tetracycline compounds
06/01/2005EP1534299A2 Methods for treating psychosis associated with interferon-alpha therapy
06/01/2005EP1534298A2 Novel anticholesterol compositions and method for using same
06/01/2005EP1534297A1 Methods of treatment of male erectile dysfunction
06/01/2005EP1534296A1 Use of a specific cyclic amine derivative or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure
06/01/2005EP1534295A1 Formulations and methods of administration of cephalotaxines, including homoharringtonine
06/01/2005EP1534294A1 Broad-spectrum anti-emetic compositions and associated methods
06/01/2005EP1534293A1 Anti-inflammatory compositions and methods of use
06/01/2005EP1534292A2 Protease inhibitors
06/01/2005EP1534290A2 Novel inhibitors of kinases
06/01/2005EP1534289A1 Adenosine a2a receptor antagonists for treating restless legs syndrome or related disorders
06/01/2005EP1534288A1 Stable aqueous solutions of risperidone and methods for their preparation
06/01/2005EP1534287A1 Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
06/01/2005EP1534286A1 Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
06/01/2005EP1534285A2 Selective phosphodiesterase 9a inhibitors as medicaments for improving cognitive processes
06/01/2005EP1534284A2 Amino-substituted sulfonanilides and derivatives thereof for treating proliferative disorders
06/01/2005EP1534283A1 Formulation of liposomal derivatives of phenylalanine
06/01/2005EP1534282A2 Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
06/01/2005EP1534281A1 N-sulfonylpiperidines as metalloproteinase inhibitors (tace)
06/01/2005EP1534279A2 Prenylation inhibitors containing dimethyl-cyclobutane and methods of their synthesis and use
06/01/2005EP1534278A2 Nitrosated proton pump inhibitors, compositions and methods of use
06/01/2005EP1534277A1 Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals
06/01/2005EP1534276A2 Non-nucleoside reverse transcriptase inhibitors
06/01/2005EP1534275A1 Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals
06/01/2005EP1534274A1 Combination of an allosteric alkyne inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
06/01/2005EP1534273A2 Modulators of the glucocorticoid receptor and method
06/01/2005EP1534272A2 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4 inhibitors
06/01/2005EP1534271A1 Antitumor compound and therapeutic uses thereof
06/01/2005EP1534270A2 Carvedilol phosphate salts and/or solvates thereof, correspondinq compositions, and/or methods of treatment
06/01/2005EP1534269A1 Oxime conjugates and methods for their formation and use
06/01/2005EP1534268A2 Tyrosine kinase inhibitors
06/01/2005EP1534267A1 Pyrrolidine derivatives as tryptase inhibitors
06/01/2005EP1534265A1 Combination of an aromatase inhibitor with a bisphosphonate
06/01/2005EP1534264A2 Compounds that modulate the activity of ptp-1b and tc-ptp
06/01/2005EP1534263A2 Novel compounds, pharmaceutical compositions containing same, and methods of use for same
06/01/2005EP1534262A1 Combination of chemotherapeutic drugs for increasing antitumor activity
06/01/2005EP1534261A2 Epa and dha enriched omega-3 supplement for the treatment of dry eye, meibomianitis and xerostomia
06/01/2005EP1534260A2 Perfluorinated fatty acids for the treatment of obesity, diabetes, hyperlipidaemia, cancer and inflammation
06/01/2005EP1534259A2 Sulfonamides as potassium channel blockers
06/01/2005EP1534258A2 AGONISM OF THE 5HT 2a RECEPTOR FOR TREATMENT OF THERMOREGULATORY DYSFUNCTION
06/01/2005EP1534256A2 Immunomodulation and effect on cell processes relating to serotonin family receptors and the blood-brain barrier
06/01/2005EP1534254A2 Method of promoting smoking cessation
06/01/2005EP1534251A1 Process for the preparation of pharmaceutical microcapsules with enhanced taste-masking and high dissolution rate
06/01/2005EP1534250A2 Electrospun amorphous pharmaceutical compositions
06/01/2005EP1534248A1 Lasofoxifene tablet and its coating
06/01/2005EP1534246A1 Sustained release pharmaceutical composition of a cephalosporin antibiotic
06/01/2005EP1534245A1 Rapidly disintegrating tablet
06/01/2005EP1534242A2 Buccal, polar or non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
1 ... 4671 4672 4673 4674 4675 4676 4677 4678 4679 4680 4681 4682 4683 4684 4685 4686 4687 4688 4689 4690 4691 ... 7860